NFXF Blog
Featured
Our 2026 NFXF awards are in! Learn more about each award and the respective awardees.
FXS Tips & Support for Traveling + Free Downloads
06 mins read
Two Letters for Parents With a New Fragile X Syndrome Diagnosis
04 mins read
Congratulations to Our 2026 Jr. Investigators Awardees!
02 mins read
University of Minnesota’s Masonic Institute for the Developing Brain (MIDB)
02 mins read
All Articles
[This is an archived page referring to the Seaside Arbaclofen (STX209) clinical trial, which was terminated in 2013.] We have experienced a setback with the cancellation of the extension phase of the STX209 drug trials for Fragile X syndrome, and what have been deemed the technical failures of two other ongoing trials of this drug.
[This is an archived page referring to the Seaside Arbaclofen (STX209) clinical trial, which was terminated in 2013.] By now, many of you have heard that Seaside Therapeutics has decided to end the extension of the trial medication Arbaclofen (STX209).